Connor, Clark & Lunn Investment Management Ltd. Hutchmed (China) LTD Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$21.1 Billion
Q1 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 29,380 shares of HCM stock, worth $448,338. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,380

Previous 30,109 2.42%

Holding current value

$448,338

Previous $433,000 1.85%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$13.09 - $16.75 $9,542 - $12,210	-729 Reduced 2.42%	29,380 $441,000
Q4 2024 Feb 10, 2025	SELL	$14.25 - $21.35 $265,263 - $397,430	-18,615 Reduced 38.2%	30,109 $433,000
Q3 2024 Nov 08, 2024	BUY	$16.03 - $20.31 $388,647 - $492,415	24,245 Added 99.04%	48,724 $952,000
Q2 2024 Aug 09, 2024	SELL	$16.36 - $21.78 $321,081 - $427,454	-19,626 Reduced 44.5%	24,479 $419,000
Q1 2024 May 09, 2024	SELL	$12.08 - $18.56 $58,261 - $89,514	-4,823 Reduced 9.86%	44,105 $740,000
Q4 2023 Feb 09, 2024	BUY	$16.25 - $20.23 $369,183 - $459,605	22,719 Added 86.68%	48,928 $886,000
Q3 2023 Nov 13, 2023	BUY	$11.85 - $16.95 $310,576 - $444,242	26,209 New	26,209 $443,000
Q4 2022 Feb 10, 2023	BUY	$7.65 - $15.51 $9,371 - $18,999	1,225 Added 7.35%	17,889 $264,000
Q3 2022 Nov 10, 2022	BUY	$8.63 - $15.52 $143,810 - $258,625	16,664 New	16,664 $148,000
Q4 2021 Feb 10, 2022	SELL	$28.89 - $35.33 $365,516 - $446,995	-12,652 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$35.66 - $42.94 $451,170 - $543,276	12,652 New	12,652 $463,000

Others Institutions Holding HCM

# of Institutions

Shares Held

6.44M

Call Options Held

9.9K

Put Options Held

9.6K

View Full List

About HUTCHMED (China) Ltd

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.64B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

More about HCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Hutchmed (China) LTD Transaction History